Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
A tasting of Heath Economics from Theory to A tasting of Heath Economics from Theory to Practice: linking Research, Reimbursement Practice: linking Research, Reimbursement
and Regulationand Regulation
Eckermann July 21, 2008
Simon EckermannFlinders University
Eckermann July 21 2008
Overview
• Comparing strategies in HTA: the expected net loss frontier – linking reimbursement & research
• Practice consistent with maximising net benefit: the net benefit correspondence theorem
• Joint optimal trial design and decision making: to delay and trial, adopt now or adopt and trial?
Comparing multiple strategies in HTA
• Economic analysis undertaken in HTA attempts to inform decision makers of the relative effects and costs (resource use) of alternative strategies in treating defined patient populations
- Comparison may be between a strategy and a single comparator (bilateral) or between multiple strategies (multi-lateral)
Eckermann July 21 2008
E.g. comparing six alternative strategies for Gastro Oesophogeal Reflux Disease (GORD)
Briggs, Goeree, Blackhouse & O’Brien (2002)
5.586.1812.6710.554.867.90Expected weeks with GORD (up to 1 year)
957747 8076601088688Cost per patient
FEDCBAStrategy
Eckermann July 21 2008
F
B
E
AC
D
INMB=-3
59, k
=100
INMB=0
, k=$
100/w
k GERD av
oided
INMB=3
50, k
=$100
-$350
-$250
-$150
-$50
$50
$150
$250
$350
$450
-3 -2 -1 0 1 2 3 4 5Incremental weeks free of GERD relative to lowest cost
strategy (C)
Incr
emen
tal c
ost r
elat
ive
to lo
wes
t cos
t str
ateg
y (C
)
A=Intermittent PPIB=Maintenance PPIC=Maintenance H2RAD=Step-down maintenance PAE=Step-down maintenance H2RAF=Step-down maintenance PPIEfficiency frontier, baselineINMB=-359, k=100INMB=0, k=$100/wk GERD avoidedINMB=350, k=$100
Eckermann July 21 2008
F
B
E
AC
D
INMB=350, k=100
INMB=0, k=100/wk GERD avoided
INMB=-359, k=100
$0
$100
$200
$300
$400
$500
$600
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
Incremental weeks with GERD relative to the most effective strategy (B)
Incr
emen
tal c
ost r
elat
ive
to le
ast e
xpen
sive
str
ateg
y (C
)
A=intermittent PPIB=Maintenance PPIC=Maintenance H2RAD=Step-down maintenance PAE=Step-down maintenance H2RAF=Step down maintenance PPIEfficiency frontie, baselineINMB=350, k=100INMB=0, k=100/wk GERD avoidedINMB=-359, k=100
Eckermann July 21 2008
Advantages of efficiency frontiers on the cost-disutility plane
• Frontiers in the cost disutility plane permit equivalent identification of dominance and net benefit maximisation but …
• Radial contraction properties also allow:
(i) technically simpler construction of efficiency frontiers
(ii) degree of dominance to be estimated(iii) a bounded comparison of net benefit
(iso-net-benefit lines)
Eckermann July 21 2008
Representing uncertainty with multiple strategies
Monte-Carlo simulation allows a joint sampling distribution of costs and effects across multiple strategies to be estimated.
How can such joint distributions best be presented and summarized to inform decision making?
Eckermann July 21 2008
Distributions for GERD strategies on the incremental CE plane
-200
-100
0
100
200
300
400
500
600
-6 -4 -2 0 2 4 6 8
Incremental weeks of GERD avoded realtive to strategy C
Incr
emen
tal c
ost r
elat
ive
to s
trat
egy
C
Strategy D Strategy C Strategy A Strategy E Strategy F Strategy B
Eckermann July 21 2008
Distributions for GERD strategies on the cost-disutility plane
0
100
200
300
400
500
600
0 1 2 3 4 5 6 7 8 9 10Incremental weeks of GERD realtive to the most effective stratgey in each replicate
Incr
emen
tal c
ost r
elat
ive
to th
e ch
eape
st s
trat
egy
in e
ach
repl
icat
e
B=Maintenance PPI F=Step-down maintenance PPI E=Step-down maintenance H2RA A=Intermittent PPI C=Maintenance H2RA D=Step-down maintenance PA
Eckermann July 21 2008
Cost effectiveness acceptability curves for GERD strategies
E
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 50 100 150 200 250 300
Threshold value for $/week of GERD
Prop
ortio
n of
repl
icat
es m
axim
isin
g ne
t ben
efit
A
C
10.85 34.60 272.56
B
F
Eckermann July 21 2008
Cost effectiveness acceptability frontier for GERD strategies
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 50 100 150 200 250 300
Threshold value for $/week of GERD
Prop
ortio
n of
repl
icat
es m
axim
isin
g ne
t ben
efit
A
C
10.26 35.02 265.79
B
E
Eckermann July 21 2008
Does the CEA frontier inform risk neutral or somewhat risk averse DM
• Risk neutral - interested in max. ENBCEA frontier while indicating strategy max ENB doesn’t explain why – lacks transparency
• Risk averse – trade off ENB and P(max NB)CEA frontier doesn’t present ENB
In either case representing difference in ENB across strategies is suggested
Eckermann July 21 2008
Eckermann July 21 2008
The expected net loss frontier
Eckermann, Briggs and Willan (2008)
C
A
E
F
CFD
D
0
50
100
150
200
250
0 50 100 150 200 250 300
Threshold value for $/week of GERD
loss
in e
xpec
ted
net m
onet
ary
benf
it ($
/per
pat
ient
) for
GER
D s
trat
egie
s
A
A EB
B
E
E
10.26 35.02 265.79
simultaneously identifies the strategy max.ENB and EVPI at any threshold value
Conclusions - multiple strategies
1. The cost disutility plane unlike CE plane allows:– bivariate distributions for all strategies and;– Inference P(max E), P(min C)2. NL curves and frontier directly inform risk neutral
DM, unlike CEA curves and frontier
Risk averse DM can be supplemented by tradeoffs in regions where they occur between ENB and P(max NB) from bilateral CEA curves
- prevents confounding by irrelevant strategies from CEA curves for multiple strategies
Eckermann July 21 2008
Efficiency measures in practice • Conventional measures of economic
efficiency in service industries such as health care reflect cost per service e.g. cost / admission in hospitals
• Such measures include the costs of quality but implicitly value the effects of quality at 0
• Hence perverse incentives are created for cost minimising quality of services
Eckermann July 21 2008
The challenge
• It is generally agreed that to create appropriate incentives economic efficiency measures need to include the value of the effects of quality, as well as the costs of quality
• How can we specify effects of quality in economic efficiency measures to be consistent with an appropriate underlying objective?
Eckermann July 21 2008
Efficiency measurement consistent with maximising net benefit?
F
B
E
AC
D
-$400
-$300
-$200
-$100
$0
$100
$200
$300
$400
$500
-3 -2 -1 0 1 2 3 4 5 6
Incremental weeks free of GORD relative to lowest cost strategy (C)
Incr
emen
tal c
ost (
$ C
anad
ian)
rel
ativ
e to
low
est
cost
str
ateg
y (C
)
Efficiency measures require radial (ratio) properties.
The NB formulation NB=k×ΔE-ΔC doesn’t have radial properties
However.. a linear transformation of net benefit may allow radial (ratio) properties while retaining a correspondence with maximising net benefit…
Eckermann July 21 2008
Radial properties on the cost-disutility plane
D
CA
E
B
F
$0
$100
$200
$300
$400
$500
$600
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
Incremental weeks with GORD relative to the most effective strategy (B)
Incr
emen
tal c
ost (
$ Ca
nadi
an) r
elat
ive
to le
ast
expe
nsiv
e st
rate
gy (C
) F
B
E
AC
D
-$400
-$300
-$200
-$100
$0
$100
$200
$300
$400
$500
-3 -2 -1 0 1 2 3 4 5 6
Incremental weeks free of GORD relative to lowest cost strategy (C)
Incr
emen
tal c
ost (
$ C
anad
ian)
rel
ativ
e to
low
est
cost
str
ateg
y (C
)
Eckermann July 21 2008
Net benefit correspondence theoremThere is a one-to-one correspondence between:
Maximising NB=k×E-C and Minimising C+k×DU
Where two conditions are satisfied:1. differences in expected costs and DU are adjusted
for - common comparator condition
2. effects framed from a disutility perspective (DU) cover effects of care in NB - coverage condition
Eckermann (2004), Eckermann Briggs and Willan (2008)
Eckermann July 21 2008
Comparing provider efficiency on the cost-disutility plane
$0
$2 ,000
$4 ,000
$6 ,000
$8 ,000
$10 ,000
$12 ,000
$14 ,000
0% 10% 20% 30% 40%
mortality rate
$ pe
r ad
miss
ion
45 NSW hospitals
frontier minimising costper admission| mortalityrate
isocost, k=$30000 perlife saved
radial contraction tofrontier (TE) and iscost(economic efficiency)
Eckermann July 21 2008
Minimum C+k×DU
k=$0 k=$10,000 k=$25,000 k=$50,000 Minimum
C/E Hospital
1 0.74 0.54 0.41 0.28 0.53 2 0.39 0.41 0.4 0.32 0.35 3 0.45 0.54 0.61 0.58 0.49 4 0.29 0.37 0.43 0.43 0.32 5 0.7 0.53 0.4 0.28 0.50 6 0.44 0.54 0.62 0.61 0.48 7 0.87 0.63 0.47 0.32 0.67 8 0.6 0.65 0.64 0.53 0.61 9 0.49 0.55 0.57 0.5 0.50
10 0.54 0.68 0.8 0.8 0.61 11 0.48 0.6 0.71 0.72 0.54 12 0.43 0.42 0.38 0.29 0.35 13 0.59 0.48 0.39 0.27 0.43 14 0.27 0.36 0.44 0.47 0.31 15 0.54 0.63 0.66 0.59 0.58 16 0.58 0.55 0.49 0.37 0.52 17 0.93 1.00 0.99 0.81 1.00 18 0.48 0.49 0.45 0.36 0.44 19 0.79 0.84 0.81 0.66 0.83 20 0.59 0.56 0.5 0.38 0.53 21 0.48 0.54 0.56 0.49 0.49 22 0.74 0.64 0.54 0.39 0.65 23 0.61 0.6 0.56 0.43 0.57 24 0.68 0.58 0.48 0.34 0.56 25 0.79 0.72 0.62 0.46 0.74 26 1.00 0.91 0.78 0.58 0.98 27 0.59 0.71 0.8 0.76 0.65 28 0.46 0.5 0.5 0.43 0.45 29 0.68 0.75 0.75 0.64 0.71 30 0.61 0.53 0.44 0.32 0.49 31 0.65 0.66 0.62 0.49 0.64 32 0.53 0.5 0.45 0.34 0.46 33 0.68 0.85 1.00 1.00 0.78 34 0.51 0.6 0.65 0.58 0.55 35 0.48 0.49 0.46 0.36 0.44 36 0.69 0.62 0.53 0.39 0.62 37 0.62 0.54 0.46 0.34 0.51 38 0.52 0.52 0.48 0.38 0.47 39 0.56 0.5 0.43 0.32 0.46 40 0.61 0.6 0.55 0.43 0.57 41 0.64 0.57 0.48 0.35 0.54 42 0.51 0.52 0.49 0.39 0.47 43 0.67 0.55 0.45 0.31 0.53 44 0.47 0.46 0.42 0.33 0.41 45 0.53 0.5 0.44 0.33 0.45
Decomposing net benefit efficiency into technical efficiency of net benefit (minimising cost per service| DUE ) and allocative efficiency
technical efficiency of provider at P=OQ/OP with value of effects k: economic efficiency for provider at P=OR/OP allocative efficiency for provider at P=OR/OQ
Cost /service ($)
DUE
P
A
S
T
Q
T’
R
A’ 0
k
Eckermann July 21 2008
Technical efficiency under constant and variable returns to scale
0.801.000.8010
0.860.680.589
0.790.820.658
0.880.980.877
0.621.000.626
0.830.840.705
0.471.000.474
0.611.000.613
0.560.740.412
0.741.000.741
Scale efficiency
Technical efficiency (variable returns to
scale)
Technical efficiency (constant returns
to scale)Hospital
Eckermann July 21 2008
Back-solving to identify where technically efficient providers max NB
Comparing adjacent technically efficient hospitals on the frontier:
• Hospital 27 benchmark $0 to $3523 per death avoided;
• Hospital 18 from $3524 to $24,356 per death avoided;
• Hospital 34 beyond $24356 per death avoided
( ) /( )i i j j
j i i j
C DU k C DU k
k C C DU DU
+ × = + ×
⇔ = − −
Eckermann July 21 2008
Shadow price for health effects where industry economic efficiency - weighted by provider cost share is maximised
0%
10%
20%
30%
40%
50%
60%
70%
$0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 $35,000 $40,000 $45,000 $50,000
value of additional survivor
cost
sha
re w
eigh
t eco
nom
ic
effic
ienc
y ac
ross
hos
pita
ls Shadow price industry behaviour = $3523/death avoided
Eckermann July 21 2008
Satisfying comparability & coverageTo satisfy comparability condition • requires risk factors adjustment • necessary and sufficient to prevent cream-
skimming
To satisfy coverage condition • systematically identify and measure effects
including those beyond service (data linkage)• necessary and sufficient to prevent cost-
shifting
Qualification required where conditions not satisfiedEckermann July 21 2008
Conclusions – measuring efficiency Applying the net benefit correspondence theorem allows:• An intuitive story of economic, technical, allocative and scale efficiency
consistent with maximising net benefit
• Identification of efficient peers and thresholds where they maximise NB
• the shadow price for effects (quality of service) across provider behaviour
Comparability and coverage conditions also: • provide a robust framework to prevent cream-skimming and cost-shifting
incentives - supports data linkage, risk factor adjustment
.. And extends to budget constrained funding consistent with maximising NB
Eckermann (2004)
Eckermann July 21 2008
Eckermann July 21 2008
VoI and decision making within jurisdiction
• Decision makers with evidence of positive but uncertain net benefit of a new therapy can choose between:
1. delay & trial (DT)
2. adopt and trial (AT)
3. adopt with no trial (AN)
How can VoI methods inform this choice?
0 b=INMB
P(b)
Eckermann July 21 2008
Expected value of perfect information (EVPI)
EVPI – the expected value of losses avoided with perfect information can be estimated for current evidence by
integrating across the distribution of INB below 0
L(b) = -b
Eckermann July 21 2008
EVSI per patient | prior density of INB (b) and trial size n
0
L(b) = -b
( )0f b
0b b
L(b) = 0( )EVSI n
( )1E(f b | n)
Additional information is ex-ante expected to reduce the likelihood, and extent of losses integrated across INB < 0
Eckermann and Willan (2007)
Eckermann July 21 2008
An implicit assumption with adoption
• EVPI and EVSI implicitly assume that the avoiding of losses with perfect information is costless
• However.. expected costs of reversal (Cr) are faced if the new therapy is adopted at the same time a trial is undertaken (AT)
• Cr include: costs of reversing public health messages + unamortised costs of technology and training
Eckermann July 10 2008
)(bP
EVSI (adopt, n | Cr)integrates losses fordensities belowthe negative cost of reversal/patient
( )revC
N t b
For irreversible decisions EVSI =0more generally EVSI falls with costs of reversal
EVSI with Adoption | costs of reversal
Eckermann and Willan (2007, 2008)
Eckermann July 21 2008
Comparing AT, DT and AN
• Adopt and trial (AT) - EVSI reduced by costs of reversal
however
• Delay and trial (DT) - additional opportunity costs of delay for patients treated outside the trial setting
Hence a trade-off arises between the value and cost of trial information | decision context (adopt or delay)
and
• Adopt and no trial (AN) - preferred if expected net gain (value less cost) is not positive for any feasible trial
Eckermann July 21 2008
VOI and optimal decision making “within jurisdiction”
• Optimal DM with evidence of positive but uncertain net benefit
Maximise ENG for feasible local trial designs (n) with: 1. DT vs AN | opp. cost delay
and2. AT vs AN | costs reversal
0 b=INMB
P(b)
Eckermann and Willan (2007, 2008a,b)Expected value of information and decision making in HTA Option value of delay in HTA, Time and EVSI wait for no patient
General impact on decision making & trial design
• Establishes joint nature of optimal research and reimbursement
• Identifies optimal trial design for DT | opportunity cost of delay
• Costs of reversal reduce EVSI and ENG of AT – and hence: 1. AT less likely optimal and 2. Optimal trial smaller when AT is optimal
Within jurisdiction - AT infeasible / unethical when have positive net clinical benefit – informed patients prefer treatment outside trial to chance of new therapy in trial - DT vs AN relevant comparison
However AT feasible moving beyond “within jurisdiction”
Globally optimal trial design for local decision making, Eckermann & Willan (2008c)
Eckermann July 21 2008
Eckermann July 21 2008
Linking research, reimbursement & practice
• Comparing loss in net benefit (net loss) on the cost-disutility plane (Eckermann 2004) naturally leads to:
1. Performance (efficiency) measurement consistent with net benefit maximisation in practice (Eckermann 2004)
2. The expected net loss frontier - linking research and reimbursement in HTA (Eckermann Briggs and Willan, 2008)
…further supporting joint nature of optimal research and reimbursement decisions using VOI methods(Eckermann and Willan 2007, 2008a, 2008b, 2008c)
Eckermann July 21 2008
References
• Eckermann S, Briggs A, Willan A. (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making. 2008; 28: 172-181.
• Eckermann S, Briggs A, Willan A. (2005) The cost-disutility plane: a framework for evidence based medicine in practice. MDM Society 2005 conference.
• Eckermann S. (2004) “Hospital performance including quality: creating incentives consistent with evidence-based medicine” PhD Dissertation, UNSW, Sydney. http://www.library.unsw.edu.au/~thesis/adt-NUN/public/adt-NUN20051018.135506/
• Eckermann S, Willan AR (2007) . Expected Value of Information and Decision Making in HTA. Health Economics 2007; 16:195-209.
• Eckermann S, Willan AR. (2008a). The option value of delay in health technology assessment. Medical Decision Making. 2008; 28: 300-305.
• Eckermann S, Willan AR. (2008b). Time and EVSI wait for no Patient. Value in Health. 2008; 11: 522-526.
• Eckermann S, Willan AR. 2008c. Globally optimal trial design for local decision making. Health Economics. Published Online: Apr 24 2008. DOI: 10.1002/hec.1353.